The Clinical Research E-News

Similar documents
The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office

The Clinical Research E-News

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

The Clinical Research E-News Volume 8: ISSUE 7: July 29, 2016

SKCN E-Newsletter Volume 10 ISSUE 5 Regional Network Office

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

National Cancer Institute Clinical Trial Cooperative Groups

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Open clinical uro-oncology trials in Canada

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Open clinical uro-oncology trials in Canada

The Clinical Research E-News Volume 7: ISSUE 11: November 20, 2015

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted.

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Navigating Alliance Protocols

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

The RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

EASTERN COOPERATIVE ONCOLOGY GROUP

Clinical Trial Credentialing:

CancerPACT Cancer Patients Alliance for Clinical Trials

Philip Kantoff, MD Dana-Farber Cancer Institute

Logistics of Alchemist Screening Trial A Alliance Fall Group Meeting CRP Breakout Session November 5, 2015

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups

For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

CancerPACT Cancer Patients Alliance for Clinical Trials

Open clinical uro-oncology trials in Canada

Neuro-Oncology Program

Arm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.

Open clinical uro-oncology trials in Canada

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES

Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012

TRB 97th Annual Meeting

Erbitux. Erbitux (cetuximab) Description

Clinical Trials OPEN to ENROLLMENT

Tarceva. Tarceva (erlotinib) Description

TRANSPORTATION RESEARCH BOARD. TRB 98th Annual Meeting January 13-17, 2019 How to Survive and Thrive. Title goes here

THE TARGET. News from the Department of Radiation Oncology

NCCN National Comprehensive Cancer Network Directory Information

CancerPACT Cancer Patients Alliance for Clinical Trials

Cancer Registry Report. Cancer Focus: Melanoma

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.

SKCN E-Newsletter Volume 9 ISSUE 10 Regional Network Office

CLINICAL TRIALS ACC. Jul 2016

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Our Clinical Trials. Oncology

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

Ipilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Early Chemotherapy for Metastatic Prostate Cancer

Breast Cancer Clinical Trials in Georgia

Transcription:

Volume 2: ISSUE 8: April 21, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5:30pm on May 10, 2010 at the Loews Hotel. Coming soon: NSABP FC-6, A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mfolfox7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver E2508, A Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients with (Bevacizumab-eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC) E3903, Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders. RTOG0627, Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme, will be opened to the JKCCN only SWOG0521, A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III. ECOG 3805,CHAARTED - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

CALGB 70604, A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer RTOG 0937, Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) RTOG 0915, Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer RTOG 0618, A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer ECOG 1697, Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A, 3 (microscopic) Melanoma CALGB10403, An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) If your site is interested in participating in any of these studies please contact Rolma Gano at 215-955-7954 or Rolma.gano@jeffersonhospital.org. Regulatory Update: The following studies have had recent consent form changes or updated letters posted on the repository website: E4A03 R0413 R0227 S0307 (closure to accrual letter)

E1508 VELOUR C40502 E3903 R0413 NSABP FB6 R0413 (amendment #4 letter) BETH E2905 If any of these studies pertain to your site please visit the repository at: http://www.kimmelcancercenter.org/kcc/jkccn/file-repository/. Please contact Rolma Gano with any repository or other regulatory related questions. Quality Assurance Update: Please contact Kelly Shipman with any QA related issues at 215-955-2135 or Kelly.shipman@jeffersonhospital.org. CTSU Update: The following protocols are now available on the OPEN system: E2804, E1208 and E1A06. Please see the OPEN tab on the CTSU Members web site for more information about the protocols in OPEN. SWOG0421, Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer, will permanently close to accrual effective May 1, 2010 as it has met its accrual goal. If you have a CTSU related question please contact Joshua Schoppe at 215-955-0048 or Joshua.schoppe@jeffersonhospital.org. ECOG Update: ECOG Spring Meeting: The ECOG spring meeting will be held at the JW Marriott Hotel in Washington, D.C., June 11 th through the 13 th. Meeting registration will be done online again for this meeting. To register for the

Group Meeting, please use the link below. Please note that the schedule is updated on an ongoing basis. The schedule provided is for current reference only and is subject to change at any time. ECOG strongly recommends that all meeting attendees check the most current schedule online before making travel arrangements, as ECOG will not be responsible for ticket change fees due to scheduling changes. https://www.regonline.com/ecog_spring2010 If you have an ECOG related question please contact Joshua Schoppe. NSABP Update: NSABP audit: Please mark your calendar for the NSABP audit scheduled for June 21, 2010. The chart of any JKCCN NSABP patient accrued in the last 3 years may be selected for audit. We will be notified of the announced charts on May 24, 2010. STAR: A reanalysis of STAR data with 81 months of follow-up has been completed. STAR investigators presented this update and additional data at the 101st Annual Meeting of the American Association for Cancer Research (AACR) in Washington D.C. on Monday, April 19th. A comprehensive article reporting the trial and analysis was published in this week's NCI Cancer Bulletin. Follow up for the participants in the STAR trial is challenging, but this reanalysis demonstrates the importance of long term data. A special thank you to our hard-working STAR coordinators! The link to the NCI bulletin publication is below: http://www.cancer.gov/ncicancerbulletin/042010 If you have an NSABP related question please contact Vicki Squire at vicki.squire@jeffersonhospital.org or at 215-503-5641.

RTOG Update: The next RTOG Semiannual meeting will be held June 17-20, 2010, at the Loews Philadelphia Hotel in Philadelphia, PA. General information about the meeting can be found at http://rtog.org/meeting/main.html. Please preregister via the following link: https://registrations.acr.org/rtog/. Jefferson Oncology Group (JOG) Update: If your site has any JOG inquires please contact either Josh Schoppe or Vicki Squire. Jefferson Kimmel Cancer Center Network Homepage: http://www.kimmelcancercenter.org/jkccn/. This page contains links to the Remote Access Portal as well as the clinical trial document repository. Upcoming Events: NSABP Group Meeting, San Francisco: April 22-25 JOG Investigator Meeting, Philadelphia: May 10 ECOG Spring Meeting, Washington, D.C.: June 11-13 RTOG Semiannual Meeting, Philadelphia, PA: June 17-20 The Clinical Research E-News Archive is now located on the Kimmel Cancer Center webpage under the JKCCN Member Area: http://www.kimmelcancercenter.org/jkccn/e-newsletters.html Please provide feedback and any suggestions to Joshua Schoppe at 215-955- 0448 or email Joshua.schoppe@jeffersonhospital.org